Physician profile
David J Sandercock
NPI 1871672436
$7,470.64
in general payments reported to CMS, 2019-2025
62 companies · $1,239 in 2025
The $1,239 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $938 · 2020: $611 · 2021: $1,310 · 2022: $1,169 · 2023: $1,057 · 2024: $1,147 · 2025: $1,239.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,443.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,442.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,083.29 | 2020-2025 | Qulipta, Ubrelvy, Vraylar |
| Novo Nordisk INC | $713.67 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $705.40 | 2019-2025 | |
| Lilly USA, LLC | $484.27 | 2019-2025 | Mounjaro, Zepbound, Emgality |
| Glaxosmithkline, LLC. | $416.41 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $376.10 | 2019-2025 | Repatha, Otezla, Otezla |
| Amarin Pharma, INC. | $334.03 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $284.48 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $280.13 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $239.63 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Boehringer Ingelheim Pharmaceuticals, INC. | $194.06 | 2019-2024 | Ofev |
| Bayer Healthcare Pharmaceuticals INC. | $183.32 | 2021-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $169.64 | 2022 | |
| Esperion Therapeutics, INC. | $163.46 | 2020-2025 | Nexletol |
| Sanofi Pasteur INC. | $120.74 | 2022-2023 |
Show all 61 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Sandercock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.